產(chǎn)品搜索
相關(guān)文章
- 羅氏免疫療法獲FDA批準(zhǔn)治療晚期非小細(xì)胞肺癌(NSCLC)
- 從諾輝財(cái)報(bào)看甲基化市場(chǎng),科佰生物助力甲基化標(biāo)準(zhǔn)品的開發(fā)
- GLP1R藥靶篩選模型應(yīng)用展示
- 拯救偏頭痛!CGRP及其受體拮抗劑研究進(jìn)展
- 【產(chǎn)品推介】RANKL抗體篩選模型
- ATCC細(xì)胞的實(shí)驗(yàn)要點(diǎn)及說(shuō)明
- CD27細(xì)胞篩選模型
- 黑色素瘤研究進(jìn)展一覽
- CD200/CD200R篩選模型
- 認(rèn)識(shí)下北京細(xì)胞庫(kù)的質(zhì)量管理要求
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73284c-Kit W557_K558del-T670I/BaF3

- 詳細(xì)內(nèi)容
CBP73284 | |
I. Introduction | |
Cell Line Name: | c-Kit W557_K558del-T670I/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
KIT W557_K558del results in the deletion of 2 amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 557 to 558 (PMID: 12918066). W557_K558del results in constitutive activation of Kit and increased Erk phosphorylation, and leads to increased invasiveness and expression of ETV1 in cell culture (PMID: 25239608, PMID: 26936919). | |
III. Representative Data | |
1. c-Kit W557_K558del-T670I/BaF3 | |
2.Sanger of c-Kit W557_K558del-T670I/BaF3 Figure 2. c-Kit W557_K558del-T670I/BaF3 T670I Figure 3. c-Kit W557_K558del-T670I/BaF3 W557_K558del | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 C-KIT W557_ K558del/T670I (C8). | |
|